Mylan finalises $465m deal with US government over EpiPen

08:50 EDT 18 Aug 2017 | pharmaphorum

Mylan has finalised an agreement to pay the US government $465 million, resolving a case accusing the pharma company of overcharging for its EpiPen anti-allergy pen. EpiPens provide a potentially life-saving shot of epinephrine for people who have...

Original Article: Mylan finalises $465m deal with US government over EpiPen


More From BioPortfolio on "Mylan finalises $465m deal with US government over EpiPen"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...